Cathie Wood’s ARK sells Tempus AI stock, buys Veracyte

Cathie Wood's ARK ETF reported significant portfolio adjustments on August 27th, 2026, focusing on divestments from Tempus AI and Twist Bioscience, while increasing investments in Veracyte and Scribe Therapeutics. The ETF sold 59,276 shares of Tempus AI, worth $4,059,220, and 22,225 shares of Twist Bioscience for $3,335,083, both part of their ongoing strategy to reduce exposure in these technology stocks.

On the buying front, ARK acquired 47,793 shares of Veracyte for $2,116,751 and added 5,085 shares of Scribe Therapeutics, totaling $161,194, highlighting a strategic pivot towards biotechnology. These moves reflect ARK’s continued emphasis on biotech investments amidst broader portfolio rebalancing.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.